269 related articles for article (PubMed ID: 25324418)
1. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose.
Sutou I; Nakatani T; Hashimoto T; Saito Y
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):161-5. PubMed ID: 26095488
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
[TBL] [Abstract][Full Text] [Related]
5. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Morikawa N; Kasahara Y; Takahashi Y; Nishikura K; Nishihara M
Biol Pharm Bull; 2019; 42(10):1674-1678. PubMed ID: 31582655
[TBL] [Abstract][Full Text] [Related]
7. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
8. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
[TBL] [Abstract][Full Text] [Related]
10. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
12. [Opioid combination of transdermal fentanyl and oral oxycodone for pain in a patient with giant-cell tumor of the sacrum].
Yoshitake A; Yamamoto T; Susaki S; Abe E
Masui; 2014 Feb; 63(2):199-202. PubMed ID: 24601119
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
15. The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain.
Reddy A; Yennurajalingam S; Reddy S; Wu J; Liu D; Dev R; Bruera E
J Pain Symptom Manage; 2016 Jun; 51(6):1040-5. PubMed ID: 26826675
[TBL] [Abstract][Full Text] [Related]
16. Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain.
Heiskanen T; Langel K; Gunnar T; Lillsunde P; Kalso EA
J Pain Symptom Manage; 2015 Oct; 50(4):524-32. PubMed ID: 25242020
[TBL] [Abstract][Full Text] [Related]
17. [Switching from oral oxycodone to oxycodone injection - an investigation into the dosage amount ratio].
Oda K; Kamiyama H; Goda Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):63-6. PubMed ID: 25596681
[TBL] [Abstract][Full Text] [Related]
18. Modified glasgow prognostic score predicting high conversion ratio in opioid switching from oral oxycodone to transdermal fentanyl in patients with cancer pain.
Jia SS; Shang L; Li ME; Zhao DM; Xu WH; Wang YQ
Int J Clin Exp Med; 2015; 8(5):7606-12. PubMed ID: 26221306
[TBL] [Abstract][Full Text] [Related]
19. Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
Chapman CR; Bradshaw DH
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):370-7. PubMed ID: 24143927
[TBL] [Abstract][Full Text] [Related]
20. Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
O'Bryant CL; Linnebur SA; Yamashita TE; Kutner JS
J Pain Palliat Care Pharmacother; 2008; 22(4):282-90. PubMed ID: 21923312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
